KPTI
Karyopharm Therapeutics Inc
1.80$
-3.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 94.3% | 82.4% | 73.0% | 82.3% | 98.1% | 92.8% | 92.5% | 90.3% | 97.8% | 97.3% | 95.2% | 95.1% | |
| 68.4% | 27.1% | 27.5% | 38.3% | 34.6% | 43.7% | 27.4% | 62.4% | 37.7% | 21.7% | 38.0% | 55.8% | |
| 93.4% | 81.5% | 71.8% | 81.2% | 96.2% | 89.5% | 87.4% | 74.9% | 77.6% | 79.6% | 66.1% | 58.8% | |
| – | – | – | – | – | 2.7% | 4.1% | 7.4% | 13.1% | 11.2% | 18.7% | 24.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 0.1% | 0.8% | 1.3% | 1.2% | 1.3% | 2.9% | 3.7% | |
| 1.2% | 1.6% | 1.6% | 1.2% | 1.1% | 1.0% | 0.7% | 0.5% | 0.3% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 6.1% | 7.9% | 10.1% | 28.2% | 46.3% | 83.1% | 83.9% | 126.1% | 104.7% | 156.6% | 213.1% | 370.2% | |
| 5.6% | 7.0% | 9.1% | 27.4% | 13.7% | 15.7% | 0.1% | 24.1% | 18.4% | 28.9% | 56.1% | 84.9% | |
| – | – | – | 12.1% | 9.6% | 0.6% | 0.6% | 0.8% | 0.8% | 1.4% | 15.1% | 20.3% | |
| 2.9% | 1.8% | 2.6% | 3.1% | 1.3% | 0.3% | 1.4% | 0.5% | 0.8% | 1.3% | 3.1% | 3.7% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 30.1% | 37.2% | 37.7% | 55.5% | 47.5% | 71.1% | 99.1% | 189.9% | |
| 93.9% | 92.1% | 89.9% | 71.8% | 53.7% | 16.9% | 16.1% | -26.1% | -4.7% | -56.6% | -113.1% | -270.2% | |
| -62.8% | -119.1% | -203.0% | -274.7% | -197.5% | -296.1% | -341.7% | -386.1% | -375.2% | -618.5% | -950.9% | -1,622.9% | |
| 0.9% | 1.1% | 1.4% | 1.7% | 16.6% | 21.0% | 23.0% | 1.6% | 1.5% | 3.2% | 4.9% | 10.1% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.